1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights, 2016


DelveInsight’s, “ Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Wet (Neovascular / Exudative) Macular Degeneration. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Wet (Neovascular / Exudative) Macular Degeneration. DelveInsight’s Report also assesses the Wet (Neovascular / Exudative) Macular Degeneration therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Wet (Neovascular / Exudative) Macular Degeneration-Pipeline Insights, 2016

Illustrative Table of contents

- Wet (Neovascular / Exudative) Macular Degeneration Overview
- Wet (Neovascular / Exudative) Macular Degeneration Pipeline Therapeutics
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutics under Development by Companies
- Wet (Neovascular / Exudative) Macular Degeneration Filed and Phase III Products
- Comparative Analysis
- Wet (Neovascular / Exudative) Macular Degeneration Phase II Products
- Comparative Analysis
- Wet (Neovascular / Exudative) Macular Degeneration Phase I and IND Filed Products
- Comparative Analysis
- Wet (Neovascular / Exudative) Macular Degeneration Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products
- Wet (Neovascular / Exudative) Macular Degeneration - Dormant Products
- Companies Involved in Therapeutics Development for Wet (Neovascular / Exudative) Macular Degeneration
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Monotherapy Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Combination Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Discontinued Products
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Monotherapy Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Combination Products
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Route of Administration
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Molecule Type
- Wet (Neovascular / Exudative) Macular Degeneration Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

Ophthalmic Lasers Market by Product Type, Application, & End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The ophthalmic lasers market is projected to reach USD 1,245.4 million by 2021 from USD 970.2 million in 2016, at a CAGR of 5.1%. Increasing prevalence of ophthalmic disorders, increasing prevalence of ...

Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period

Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period

  • $ 4995
  • Industry report
  • August 2016
  • by GBI Research

Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period Summary Ophthalmology is a therapy area that deals with the diagnosis, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.